Yahoo · Oct 30, 2026
How This Under-the-Radar Quantum Stock Could More Than Double
Pasqal’s neutral-atom architecture and practical commercial road map will drive massive upside, Cantor Fitzgerald says.
NASDAQ · IBM
International Business Machines Corporation
Technology · Information Technology Services
$257.81
Down-$0.47 (-0.18%)
Updated Oct 31, 2026, 11:44 PM
SID Score
6.9/10
Composite research score
Smart Money
61/100
Neutral
- Market cap
- 290.29B
- P/E ratio
- 36.68
- Dividend yield
- 2.60%
- 52-week range
- $199.19 – $332.46
- Volume
- 5.74M
- Avg. volume
- 5.25M
Price performance · IBM
IBM price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
IBM closed at $257.81 after 21 trading sessions, up 15.80% for the selected period.
- Last close
- $257.81
- Period change
- +15.80%
- Period low
- $220.51
- Period high
- $258.28
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $258.28 | $259.59 | $254.7105 | $257.81 | 5.74M |
| Oct 29, 2026 | $249.27 | $258.33 | $247.8001 | $258.28 | 3.93M |
| Oct 28, 2026 | $248.49 | $253.85 | $247.67 | $253.22 | 3.71M |
| Oct 27, 2026 | $251.9325 | $253.18 | $249.125 | $250.25 | 3.66M |
| Oct 26, 2026 | $253.01 | $256.00 | $250.80 | $253.44 | 3.75M |
| Oct 23, 2026 | $249.73 | $254.71 | $247.03 | $253.56 | 5.89M |
| Oct 22, 2026 | $241.245 | $256.30 | $240.00 | $252.11 | 11.63M |
| Oct 21, 2026 | $241.915 | $251.75 | $240.62 | $251.46 | 10.03M |
| Oct 20, 2026 | $236.08 | $242.525 | $236.00 | $241.92 | 5.75M |
| Oct 19, 2026 | $230.68 | $238.38 | $229.2965 | $236.39 | 4.91M |
| Oct 16, 2026 | $236.05 | $236.98 | $230.25 | $232.14 | 6.96M |
| Oct 15, 2026 | $226.36 | $234.14 | $226.01 | $234.12 | 5.6M |
| Oct 14, 2026 | $231.13 | $233.14 | $227.49 | $227.88 | 4.05M |
| Oct 13, 2026 | $228.215 | $233.50 | $227.277 | $230.78 | 5.12M |
| Oct 12, 2026 | $228.31 | $229.285 | $224.77 | $227.02 | 2.76M |
| Oct 9, 2026 | $225.87 | $228.76 | $224.0501 | $227.13 | 3.35M |
| Oct 8, 2026 | $220.15 | $227.305 | $217.795 | $226.61 | 8.93M |
| Oct 7, 2026 | $221.90 | $222.41 | $218.79 | $220.51 | 3.9M |
| Oct 6, 2026 | $222.71 | $224.51 | $221.00 | $221.29 | 3.94M |
| Oct 5, 2026 | $222.30 | $222.88 | $220.30 | $221.58 | 6.32M |
| Oct 2, 2026 | $225.51 | $225.915 | $221.63 | $222.64 | 7.76M |
Latest IBM news
The latest Smart Investors Daily articles mentioning IBM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
IBM research
Overview
Company profile and research snapshot.
Company profile
Incorporated in 1911, International Business Machines, or IBM, is one of the oldest technology companies in the world. It provides software, IT consulting services, and hardware to help business customers modernize their technology workflows. IBM operates in 175 countries and employs approximately 300,000 people. The company has a robust roster of business partners to service its clients, which includes 95% of all Fortune 500 companies. IBM's products, including Red Hat, watsonx, and mainframes, handle some of the world's most important data workloads in areas like finance and retail.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $293.86
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 22, 2026 | Stifel | Buy | — |
| Oct 22, 2026 | JP Morgan | Overweight | — |
| Oct 22, 2026 | Susquehanna | Neutral | — |
| Oct 22, 2026 | Baird | Neutral | — |
| Oct 22, 2026 | Jefferies | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 30, 2026
Global Clinical Knowledge Graphs for Genomics Market Report 2026 | Capitalize on 20.7% CAGR as Microsoft, IBM, Illumina and Genomenon Scale AI, Cloud and Precision Medicine
Boost ROI with cloud-based AI, genomic data integration, variant interpretation, predictive analytics and custom knowledge modeling for precision medicine and drug discovery.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Clinical Knowledge Graphs for Genomics Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global clinical knowledge graphs for genomics market is experiencing rapid expansion as healthcare providers, researchers, and life sciences organizations seek
Yahoo · Oct 30, 2026
Why Should You Pay Attention To QBTS Stock?
For questions about this article or underlying research, email [email protected].
Yahoo · Oct 30, 2026
Can Accenture Stock Rise 30% From Here?
For questions about this article or underlying research, email [email protected].
AI research layers
Interpretive context generated from the platform’s current data sources.
IBM Stock Performance
International Business Machines Corporation shares closed at $257.81, reflecting a single-session decline of approximately 1.10%, per SID market data. Over the trailing one-month period, IBM has gained $14.27, while the three-month return shows an increase of $13.92, indicating sustained upward momentum in the intermediate term. However, the one-year change registers a decline of $14.77, underscoring longer-term underperformance. Technically, the stock trades well above its 50-day moving average of $235.17 and its 200-day moving average of $244.54, according to Massive/Polygon data. The 14-day relative strength index stands at 82.0, placing IBM firmly in overbought territory and suggesting the recent rally may be extended. The stock's beta of 0.689 indicates lower volatility relative to the broader market. Average daily volume is approximately 5.25 million shares, supporting adequate liquidity for institutional participants. IBM's current market capitalization stands at roughly $290.3 billion.
IBM Valuation Analysis
International Business Machines Corporation currently trades at a price-to-earnings ratio of 36.68, a notable premium relative to the broader technology sector's historical averages, according to SID market data. The PEG ratio stands at 1.03, suggesting the stock is approximately fairly valued when accounting for its projected earnings growth rate, per SEC filings. IBM's price-to-book ratio of 10.39 reflects significant goodwill and intangible assets on its balance sheet, largely attributable to its strategic acquisitions including Red Hat. The company offers a dividend yield of approximately 2.16%, providing income-oriented investors with a meaningful return component that distinguishes IBM from many high-growth technology peers. At a market capitalization of $290.3 billion, IBM is positioned as a large-cap technology name. The elevated P/E multiple suggests the market is pricing in continued momentum from hybrid cloud and artificial intelligence initiatives, while the near-parity PEG ratio indicates growth expectations are broadly aligned with current valuation levels.
Smart Money Activity for IBM
IBM's composite smart money score registers at 61 out of 100, reflecting a neutral overall signal, according to SID market data. The institutional component scores a perfect 25 out of 25, indicating robust accumulation by large asset managers and pension funds. In contrast, the insider trading sub-score stands at 13.2 out of 25, with dark pool activity scoring 12.2 out of 25 and congressional trading activity at 10.7 out of 25. Per SEC Form 4 filings, IBM recorded 14 insider transactions over the most recent 90-day period, with a notably bullish skew of 13 purchases versus just one sale. This strong insider buying pattern suggests that company executives and directors have demonstrated confidence in IBM's forward trajectory by committing personal capital. The institutional score of 25 out of 25, based on 13F institutional filings, confirms that major fund managers maintain or are increasing their positions. The divergence between high institutional conviction and moderate dark pool activity warrants continued monitoring for shifts in positioning among sophisticated market participants.
IBM Earnings Outlook
International Business Machines Corporation has delivered a mixed but largely positive earnings trajectory over the past four quarters, according to company earnings reports. In the most recent quarter, IBM reported earnings per share of $2.95 against analyst estimates of $2.87, representing a positive surprise of $0.08. The prior quarter saw a rare miss, with actual EPS of $2.93 falling short of the $3.02 consensus estimate by $0.09. Earlier periods reflected stronger outperformance, including a $0.21 beat in Q4 when IBM posted $4.52 versus the $4.31 estimate, and a $0.10 beat in Q3 with $1.91 actual versus $1.81 estimated. Across the four reported quarters, IBM exceeded consensus expectations in three instances, per analyst estimates. The Q4 result of $4.52 EPS marked the highest quarterly earnings figure in the trailing period, reflecting typical seasonality in enterprise software and services spending. The aggregate trend indicates management's consistent ability to meet or exceed Street expectations.
Wall Street Analyst Ratings for IBM
Wall Street coverage of International Business Machines Corporation reflects a moderately constructive consensus, per SID consensus data. In the most recent round of analyst updates dated October 22, 2026, five major firms reiterated their existing ratings. Stifel maintained a Buy rating, while JP Morgan reaffirmed its Overweight stance, both signaling continued confidence in IBM's strategic positioning, according to Wall Street analyst reports. Jefferies also reiterated its Buy rating, providing a third bullish endorsement among the latest updates. On the neutral side, both Susquehanna and Baird maintained their Neutral ratings, indicating a more cautious perspective on the risk-reward balance at current valuation levels. Notably, none of the five analysts adjusted their ratings from prior assessments, suggesting IBM's recent quarterly results were broadly in line with existing expectations. The distribution of three bullish ratings against two neutral ratings reflects a market consensus that leans positive, though the absence of any rating upgrades indicates limited catalysts for a material re-rating in the near term.
